Department of Pharmacy, Gifu University Hospital, 1-1, Yanagido, Gifu, 501-1194, Japan.
Department of Pharmacy, Hyogo Medical University Hospital, Nishinomiya, Hyogo, Japan.
AIDS Res Ther. 2023 Aug 28;20(1):62. doi: 10.1186/s12981-023-00557-5.
Long-acting injectable formulations for HIV infection have been approved and are now available in Japan. Although not currently recommended as first-line drugs in Japanese or overseas guidelines, use of such formulations may increase, in accordance with patient conditions and preference. We determine the level of satisfaction with current anti-HIV drugs and analyzed the preferences of patients who favor long-acting injectable drugs based on their satisfaction level with the present anti-HIV drugs.
People living with HIV (PLWH) who had received antiretroviral therapy (ART) for at least one month and consented to the study between 1 April and 31 December 2021 were included in a survey conducted using a self-administered questionnaire. The content of the survey included satisfaction with seven items (tablet size, ease and feeling when taking the medicine, color, taste, portability, daily oral therapy, and co-payment) related to the anti-HIV drugs they were taking and their need for future drugs (dosage form, frequency of dosing, long-acting injectable, etc.). In addition, factors related to the need for long-acting injectable medications were analyzed with regard to the relationship with satisfaction with anti-HIV drugs.
Overall, 667 patients available for analysis were included in this study. Satisfaction with anti-HIV drugs was highest with regard to "co-payment" and lowest with "daily oral therapy". Regarding the need for long-acting injectable medications, logistic regression analysis indicated that tablet size and daily oral therapy were significant predictors of patient preference for a once-every-eight-weeks intramuscular formulation in terms of their requirement for long-acting injectable medications (tablet size, OR = 2.14, 95%CI 1.030-4.430, p = 0.042; and daily oral therapy, OR = 1.75, 95%CI 1.010-3.030, p = 0.044).
Patients currently receiving anti-HIV drugs who express dissatisfaction with tablet size and daily oral therapy may prefer a long-acting injectable formulation, taking into consideration patient age, employment status, ART history, frequency of daily dosage and concomitant medications other than ART.
长效注射制剂已被批准用于治疗 HIV 感染，并在日本上市。尽管在日本或海外的指南中尚未被推荐为一线药物，但根据患者的情况和偏好，此类制剂的使用可能会增加。我们评估了患者对目前抗 HIV 药物的满意度，并根据患者对目前抗 HIV 药物的满意度分析了偏爱长效注射药物的患者的偏好。
纳入了自 2021 年 4 月 1 日至 12 月 31 日接受至少一个月抗逆转录病毒治疗（ART）并同意参加研究的 HIV 感染者（PLWH）。使用自我管理问卷进行了一项调查，调查内容包括对正在服用的抗 HIV 药物的七个项目（片剂大小、服药时的难易程度和感觉、颜色、味道、便携性、每日口服治疗和共付额）的满意度，以及对未来药物（剂型、用药频率、长效注射等）的需求。此外，还分析了与抗 HIV 药物满意度的关系，探讨了对长效注射药物需求的相关因素。
总体而言，共有 667 名可分析患者纳入本研究。对“共付额”最满意，对“每日口服治疗”最不满意。关于对长效注射药物的需求，logistic 回归分析表明，片剂大小和每日口服治疗是患者对每八周一次肌内注射制剂的偏好的显著预测因素，与他们对长效注射药物的需求相关（片剂大小，OR=2.14，95%CI 1.030-4.430，p=0.042；每日口服治疗，OR=1.75，95%CI 1.010-3.030，p=0.044）。
目前正在接受抗 HIV 药物治疗的患者，如果对片剂大小和每日口服治疗不满意，可能会偏爱长效注射制剂，同时考虑患者年龄、就业状况、ART 史、每日剂量频率以及除 ART 以外的合并用药。
